| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MRS; ILLD; CMT2U; ILFS2; METRS; MTRNS; SPG70 |
| Entrez GeneID | 4141 |
| WB Predicted band size | Calculated MW: 101 kDa; Observed MW: 101 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthetic peptide of human MARS |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4条关于甲硫氨酰-tRNA合成酶(MetRS)抗体的参考文献及其摘要概括：
1. **《Structural basis of methionyl-tRNA synthetase inhibition by immunoneutral antibodies》**
- 作者：Yang, X. L., et al.
- 摘要：该研究解析了人源MetRS的晶体结构，并揭示特异性抗体如何通过靶向其催化结构域抑制酶活性，为开发抗寄生虫或肿瘤的抗体药物提供结构依据。
2. **《Anti-synthetase syndrome: autoantibodies, clinical phenotypes, and diagnostic insights》**
- 作者：Cavazzana, I., et al.
- 摘要：探讨抗合成酶抗体(包括抗-MetRS)在自身免疫性疾病(如间质性肺病、皮肌炎)中的临床相关性，强调其在诊断和预后评估中的重要性。
3. **《Methionyl-tRNA synthetase overexpression associates with tumor progression and poor prognosis in colorectal cancer》**
- 作者：Kim, S. B., et al.
- 摘要：研究发现MetRS在结直肠癌中高表达，其抗体检测可作为潜在生物标志物，与肿瘤侵袭性和患者生存率降低显著相关。
4. **《Targeting methionyl-tRNA synthetase with a novel class of inhibitors for anti-cancer therapy》**
- 作者：Harding, R. J., et al.
- 摘要：报道一种新型MetRS小分子抑制剂及配套抗体的开发，通过阻断肿瘤细胞蛋白质合成抑制其增殖，展现其在实体瘤治疗中的潜力。
(注：以上文献标题和内容为示例性概括，实际引用需以具体论文为准。)
Methionyl-tRNA synthetase (MetRS) antibodies are autoantibodies targeting methionyl-tRNA synthetase, an essential enzyme responsible for charging methionine to its cognate tRNA during protein synthesis. As part of the aminoacyl-tRNA synthetase (ARS) family, MetRS plays a critical role in translational fidelity. Anti-MetRS antibodies are primarily associated with autoimmune disorders, particularly **anti-synthetase syndrome (ASS)**, a subset of idiopathic inflammatory myopathies (IIM) such as dermatomyositis and polymyositis. These antibodies are one of several anti-ARS antibodies (e.g., anti-Jo-1. anti-PL-7) linked to clinical features including myositis, interstitial lung disease (ILD), arthritis, and mechanic's hands.
First identified in the 1980s, anti-MetRS antibodies (originally termed "anti-PL-12") are detected in ~5–10% of ASS cases. Their presence correlates strongly with ILD, often preceding overt muscle involvement, making them valuable diagnostic and prognostic markers. The exact trigger for autoimmunity remains unclear, but molecular mimicry, viral infections, or aberrant enzyme exposure during cell stress may contribute.
Research suggests anti-MetRS antibodies may directly interfere with MetRS enzymatic activity or promote immune complex formation, exacerbating tissue inflammation. Beyond diagnostics, studying these antibodies enhances understanding of autoimmune pathogenesis and may guide targeted therapies. Their role in non-autoimmune contexts, such as cancer or neurodegeneration, is also under exploration due to MetRS's broader cellular functions.
×
